Hedgehog Fails to Help Advanced Colorectal Cancer Patients

In disappointing news, adding the Hedgehog inhibitor GDC-0449 to standard chemotherapy failed to increase the time before advanced colorectal cancer got worse.

Researchers compared progression-free survival between patients who got either FOLFOX or FOLFIRI chemotherapy with Avastin and a group who got the same chemo regimen with GDC-0449. There was no difference

GDC-0449 was being developed by Genentech in collaboration with Curis.

Hopes for the new treatment were raised at ASCO earlier this month where reports showed no increased side effects with the new combination.

Researchers thought that blocking the Hedgehog gene on the surface of cancer cells would stop a series of signalling events in a pathway inside the cell leading to cell death and lengthening the time until cancer began to grow again.

Hedgehog is involved in embryonic development, particularly in growth of limbs. It was first observed in fruit flies where mutations led to many spiky extra legs making the curled up fly look like a hedgehog. You can watch a video of how it works.

Read the news release from Curis.

Disclosure: C3 has received funding from Genentech in the form of unrestricted educational grants. C3 has ultimate control over website content.

Bookmark and Share

This news article was originally posted on June 18th, 2010 and was accurate at the time of publication. Since then, information may have changed or links may now be outdated. Please call our Answer Line 1-877-427-2111 for the latest information, or talk to your doctor before making any medical decisions.

Posted by Kate Murphy on June 18th, 2010
Tags: clinical trials, Hedgehog, metastatic colorectal cancer

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond publicly where appropriate.

Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.

We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment. For the best personal and direct response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Register to receive our free e-newsletter

Get monthly updates on colorectal cancer treatment options, research news and advocacy opportunities. We promise to not bombard you with email - just enough to keep you informed on how to fight colorectal cancer.

First Name

Last Name

Email

Donate

Support C3 and the Lisa Fund for Research

Donate to C3

Donate to The Lisa Fund

Learn more about the Lisa Fund

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe